Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 88,63 € (-5,33%). La mediana è 87,97 € (-6,04%).
| Acquista |
31 |
| Mantieni |
20 |
| Vendi |
0 |
Discussioni nella community
- Steuern auf Medtronic (IE00BTN1Y115)- Dividenden für österreichischen Aktionär
Liebe Parqet- User, weiß jemand, wie hoch die Gesamtbelastung auf eine Medtronic- Dividende ist? Das Wertpapier hat eine irische ISIN, ein Wertpapier (Accenture) hatte eine Gesamtsteuerbelastung von…
g guba IV in Schnack
0 7 - Börsen BBQ - Mein Depot zum Rösten Teil II
Hallo zusammen, nach etwas mehr als einem Jahr ist es mal wieder an der Zeit, mein Depot zum rosten zur Verfügung zu stellen. Mein Name ist Steffen, ich bin 29 Jahre alt und mittlerweile…
S Steffen I in Portfolio Roasts
3 4 - Quellensteuer Irland?
Hallo Zusammen, ich habe gerade voller Schrecken festgestellt, dass für Dividenden in Irland gelisteter Aktien zumeist eine doppelte Steuer angesetzt wird (und ich dachte immer Irland sei so toll…
Jens V in Schnack 1 18 - Börsen-BBQ: Mein Depot zum roasten
Hallo zusammen, mein Name ist Steffen, ich bin 28 Jahre alt und befinde mich im letzten Semester meines Masterstudiums. Nach meinem Studium plane ich zu promovieren und eine Stelle als…
S Steffen I in Portfolio Roasts
15 12
Notizie Vai al feed delle notizie
Medtronic launches exchange offer for MiniMed with 7% discount
Medtronic is offering its shareholders the option to exchange common shares at a 7% discount for up to 225.4 million MiniMed shares. The exchange ratio is capped at 4.5939 MiniMed shares per Medtronic common share; participating shareholders would receive MiniMed shares worth about $107.53 for every $100 of Medtronic shares, unless the cap applies. The aim is to spin off at least 80.1% of MiniMed; if oversubscribed, an additional 27.45 million shares may be exchanged, otherwise spin-off, split-off or debt-for-equity options are planned. Pricing will be based on the volume-weighted average price over three trading days ending Oct. 5–7; Medtronic shares rose 2.8% on the news. » Altro su de.investing.com
Medtronic posts strong Q1 growth, raises guidance as diabetes separation nears
Medtronic reported fiscal Q1 revenue of about $9.8 billion, up 13.7% organically, and non-GAAP EPS of $1.45, driving an increase in full-year organic revenue and EPS guidance. Cardiovascular revenue rose 18.9% with Cardiac Ablation Solutions up 88%, while Neuroscience and Medical Surgical also posted solid gains. The quarter benefited from an extra fiscal week (~$570 million) and showed only a 10 basis-point expansion in non-GAAP operating margin to 23.7%. Management is progressing with the planned MiniMed/diabetes separation and is investing in surgical robotics and Pi-Cardia, but faces competitive and margin risks going forward. » Altro su finance.yahoo.com
Medtronic posts strong revenue growth, launches Hugo robot and offers high dividend yield
Medtronic has refocused its business by exiting noncore units, spinning off its diabetes division and investing in new technology such as the Hugo surgical robot. The company reported its highest annual revenue growth in a decade in fiscal 2026 and Q1 fiscal 2027 revenues rose 13.7% with earnings above guidance, prompting an increased full-year outlook. Management says the business has passed an inflection point while the stock has gained about 15% over three months but remains roughly 30% below its 2021 high. Medtronic also retains a well-above-market dividend yield and a 48-year streak of annual dividend increases. » Altro su finance.yahoo.com
Medtronic Diabetes expects growth from broad product wave and confirms 2027 target
Medtronic Diabetes sees accelerated US growth and is preparing multiple product launches, including MiniMed Fit (FDA submission, market launch summer 2027) and Vivera (2H 2027). The company confirms its FY27 guidance for adjusted organic growth of 9–9.5% and an adjusted EBITDA margin of 16%. Management cites production ramp-up, customer buying hesitation and the trade-off between growth and margins as main risks, but highlights positive manufacturing metrics at Simplera and channel expansion, particularly via pharmacies and Type‑2 patients. » Altro su de.investing.com
Medtronic raises fiscal 2027 outlook after strong Q1 revenue and EPS beat
Medtronic reported fiscal Q1 revenue of $9.8 billion, up 13.7% organic, and adjusted EPS of $1.45, topping expectations. The company raised its full-year guidance to 7.25%–7.75% organic revenue growth and adjusted EPS of $5.94–$6.00. Cardiovascular led performance, with Cardiac Ablation Solutions up 88% worldwide (139% in the U.S.) driven by Sphere‑9 and Affera, while CRM grew 15% and gained share. Management reiterated plans to separate the MiniMed diabetes business before year‑end and continues investments in Hugo surgical robotics and a $700 million Cornerstone Robotics agreement. » Altro su finance.yahoo.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | luglio 2026 | YoY |
|---|---|---|
| Ricavi | 8,46 Mld | 12,61% |
| Utile lordo | 5,5 Mld | 26,92% |
| Utile netto | 1,27 Mld | 39,96% |
| EBITDA | 2,33 Mld | 19,44% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 119,32 Mld € |
Numero di azioni | 1,28 Mld |
Massimo/minimo a 52 settimane | 96,43 € - 66,48 € |
Rendimento da dividendo | 2,67% |
Dividendi TTM | 2,48 € |
Beta | 0,57 |
Rapporto P/E | 25,15 |
Rapporto PEG | 1,98 |
Rapporto P/B | 2,62 |
Rapporto P/S | 3,50 |
Profilo aziendale
Medtronic plc sviluppa, produce e vende terapie mediche basate su dispositivi destinate a sistemi sanitari, medici, clinici e pazienti in tutto il mondo. Il suo segmento Cardiovascular Portfolio offre pacemaker cardiaci impiantabili, defibrillatori cardioverter e dispositivi per la terapia di risincronizzazione cardiaca; prodotti per l'ablazione cardiaca; sistemi di monitoraggio cardiaco impiantabili inseribili; prodotti TYRX; e software per il monitoraggio remoto e centrato sul paziente. Fornisce inoltre valvole aortiche, prodotti per la sostituzione e la riparazione chirurgica delle valvole, endoprotesi vascolari a stent graft e accessori, e valvole polmonari transcatetere; nonché prodotti per l'intervento coronarico percutaneo, palloncini per angioplastica percutanea e prodotti. Il segmento Medical Surgical Portfolio della società offre dispositivi per suturatrici chirurgiche, strumenti per la sigillatura dei vasi, chiusura delle ferite, prodotti per l'elettrochirurgia, prodotti per l'intelligenza artificiale chirurgica e per la chirurgia assistita da robot, dispositivi meccanici per ernie, protesi in rete, prodotti per ginecologia e polmone, e varie terapie per il trattamento di malattie, nonché prodotti nei settori della diagnostica e delle terapie gastrointestinali ed epatologiche mini-invasive, del monitoraggio del paziente, della gestione delle vie aeree e delle terapie di ventilazione, e della malattia renale. Il suo segmento Neuroscience Portfolio offre prodotti per chirurghi spinali, neurochirurghi, neurologi, specialisti della gestione del dolore, anestesisti, chirurghi ortopedici, urologi, uroginecologi, radiologi interventisti, otorinolaringoiatri e sistemi che integrano strumenti chirurgici a energia. Fornisce inoltre sistemi di chirurgia guidata dalle immagini e di imaging intraoperatorio, e sistemi di guida robotica utilizzati nelle procedure robot-assistite sulla colonna vertebrale; e terapie per la vascolarizzazione all'interno e intorno al cervello. Il segmento Diabetes Operating Unit della società offre micropompe per insulina e materiali di consumo, sistemi di monitoraggio continuo del glucosio, sistemi a penna per insulina intelligenti, e materiali di consumo e forniture. La società è stata fondata nel 1949 e ha sede a Dublino, in Irlanda.
| Nome | Medtronic |
| CEO | Geoffrey Straub Martha |
| Sede centrale | Galway,
ga Irlanda |
| Sito web | |
| Settore | Sanità |
| Industria | Tecnologia sanitaria |
| Quotazione in borsa | 02/05/1973 |
| Dipendenti | 95.000 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | MDT |
London Stock Exchange | 0Y6X.L |
XETRA | 2M6.DE |
Frankfurt | 2M6.F |
Düsseldorf | 2M6.DU |
Hamburg | 2M6.HM |
Milan | 1MDT.MI |
London | 0Y6X.L |
SIX | MDT1.SW |
München | 2M6.MU |
Wien | MDT.VI |